Sugi Predict

Sugi Predict / Compounds / Angustibalin

Angustibalin

Angustibalin

SCHEMBL509228

C=C1C(=O)O[C@@H]2C[C@@H](C)[C@@H]3C=CC(=O)[C@@]3(C)[C@@H](OC(C)=O)[C@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 1.00
▸ RAB9A P51151 6/20 1.00
▸ NPC1 O15118 5/20 1.00
▸ HTT P42858 5/20 1.00
▸ XBP1 P17861 4/20 1.00
▸ MDM2 Q00987 4/20 1.00
▸ MAPK1 P28482 3/20 1.00
▸ AGTR1 P30556 3/20 1.00
▸ GPR55 Q9Y2T6 3/20 1.00
▸ PAX8 Q06710 1/20 1.00
▸ POLB P06746 4/20 0.81
▸ RECQL P46063 2/20 0.81
▸ THRB P10828 1/20 0.81
▸ OPRK1 P41145 1/20 0.81
▸ BLM P54132 1/20 0.81
▸ NPSR1 Q6W5P4 1/20 0.81
▸ TLR9 Q9NR96 1/20 0.81
▸ TERT O14746 1/20 0.72
▸ ALDH1A1 P00352 1/20 0.72
▸ GLA P06280 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bigelovin SCHEMBL29349709 1.00 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalinmethacrylate SCHEMBL31110639 0.91 MAPT (0.83) MAPTRAB9ANPC1HTTXBP1
SCHEMBL30578098 0.90 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL31237389 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL10132557 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL161593 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL10099625 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL11030579 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Helenalin SCHEMBL161594 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1
Mexicanin I SCHEMBL17238871 0.84 MAPT (1.00) MAPTRAB9ANPC1HTTXBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104968-A1 ENHANCED NK CELLS FOR CANCER IMMUNOTHERAPY HUMANITAS MIRASOLE S.P.A. (IT) 2026-05-21 — — WO disclosed
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES Didenko, Kirill (US) 2025-07-03 — — US disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 — — WO disclosed
CN-118604221-A Camellia oil and olive oil adulteration identification method based on 39 metabolic markers 长沙市食品药品检验所 2024-09-06 — — CN disclosed
WO-2023187599-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES DIDENKO KIRILL (MX) 2023-10-05 — — WO disclosed
US-20220409518-A1 EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections DESAI, KETAN 2022-12-29 — — US disclosed
EP-3366274-A1 COSMETIC BIOPHOTONIC COMPOSITIONS KLOX Technologies, Inc. (CA) 2018-08-29 — — EP disclosed
US-20170326378-A1 COSMETIC BIOPHOTONIC COMPOSITIONS KLOX TECHNOLOGIES INC. (CA) 2017-11-16 — — US disclosed
US-20170304187-A1 EMU Oil In Combination With Other Active Ingredients For Treating Skin Imperfections DESAI, KETAN 2017-10-26 — — US disclosed
US-9757324-B2 Emu oil in combination with other active ingredients for treating skin imperfections DESAI, KETAN 2017-09-12 — — US disclosed
WO-2001002028-A2 PRE-FORMED, SHEET DEVICES SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
WO-2001001933-A2 PRE-FORMED, SELF-ADHESIVE SHEET DEVICES SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
WO-2001001950-A1 PRE-FORMED GEL SHEET THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
WO-2001002477-A1 PRE-FORMED, SELF-ADHESIVE SHEETS SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
WO-2001001951-A1 SHEET-LIKE DEVICES THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
WO-2001001952-A1 DEVICES THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 — — WO disclosed
US-6153208-A A WATER INSOLUBLE SUBSTRATE HAVING A SEPARATE CLEANSING AND CONDITIONING PORTIONS WITH DIFFERENT WET EXTENSIBLE, A LATHERING SURFACTANT; DRY WASHCLOTH THE PROCTER & GAMBLE COMPANY (US) 2000-11-28 — — US disclosed
EP-1011630-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 2000-06-28 — — EP disclosed
WO-1999055303-A1 CLEANSING ARTICLES FOR SKIN AND/OR HAIR WHICH ALSO DEPOSITS SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 1999-11-04 — — WO disclosed
WO-1999013861-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 1999-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213601-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES ACE2, FURIN, SARS1 MAPT 330/4885RAB9A 1443/4885NPC1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.